As one of our main objectives is to hyper-accelerate innovation in the Pharma and MedTech industry, we are addressing several sustainable development goals (SDGs).

In particular, we are actively involved with the third SDG – Good Health and Well-being (Ensure healthy lives and promote well-being for all at all ages) with a specific focus on target 3.B – support research, development, and universal access to affordable vaccines and medicines. Our technology allows for significant cost and time savings in drug development, which results in faster-to- market medicines and medical devices.

Another goal we actively tackle is SDG 9 – Industry, Innovation, and Infrastructure (Build resilient infrastructure, promote inclusive and sustainable industrialization, and foster innovation) with a specific focus on target 9.5 – enhance research and upgrade industrial technologies.

With our platform, we want to make in silico trials more accessible to all Pharma and medical devices companies – even to SMEs and emerging BioTechs that usually don’t have the same competitive budget as established Big Pharma to perform clinical trials.

We are also committed to a long-term goal: the reduction and replacement  of animals in research since in silico trials can be used as substitutes for in vivo testing.